|
Originally published In Press as doi:10.1074/jbc.M205073200 on July 1, 2002
J. Biol. Chem., Vol. 277, Issue 37, 34101-34108, September 13, 2002
Antigenic and Functional Properties of the Human Red Blood Cell
Urea Transporter hUT-B1*
Nicole
Lucien,
Frédéric
Sidoux-Walter ,
Nathalie
Roudier,
Pierre
Ripoche,
Martine
Huet,
Marie-Marcelle
Trinh-Trang-Tan,
Jean-Pierre
Cartron§, and
Pascal
Bailly
From the INSERM U76, Institut National de la Transfusion Sanguine,
6 rue Alexandre Cabanel, 75015 Paris, France
Received for publication, May 23, 2002, and in revised form, June 28, 2002
 |
ABSTRACT |
The Kidd (JK) blood group locus encodes
the urea transporter hUT-B1, which is expressed on human red blood
cells and other tissues. The common JK*A/JK*B blood group
polymorphism is caused by a single nucleotide transition G838A changing
Asp-280 to Asn-280 on the polypeptide, and transfection of
erythroleukemic K562 cells with hUT-B1 cDNAs carrying either the
G838 or the A838 nucleotide substitutions resulted in the
isolation of stable clones that expressed the Jka or
Jkb antigens, respectively, thus providing the first direct
demonstration that the hUT-B1 gene encodes the Kidd blood
group antigens. In addition, immunochemical analysis of red blood cells
demonstrated that hUT-B1 also exhibits ABO determinants attached to the
single N-linked sugar chain at Asn-211. Moreover,
immunoadsorption studies, using inside-out and right-side-out red cell
membrane vesicles as competing antigen, demonstrated that the C- and
N-terminal ends of hUT-B1 are oriented intracellularly. Mutagenesis and
functional studies by expression in Xenopus oocytes
revealed that both cysteines Cys-25 and Cys-30 (but not alone) are
essential for plasma membrane addressing. Conversely, the transport
function was not affected by the JK*A/JK*B
polymorphism, C-terminal deletion (residues 360-389), or mutation of
the extracellular N-glycosylation consensus site and
remains poorly para-chloromercuribenzene sulfonate
(pCMBS)-sensitive. However, transport studies by stopped flow light
scattering using Jk-K562 transfectants demonstrated that the
hUT-B1-mediated urea transport is pCMBS-sensitive in an erythroid
context, as reported previously for the transporter of human red blood
cells. Mutagenesis analysis also indicated that Cys-151 and Cys-236, at
least alone, are not involved in pCMBS inhibition. Altogether, these
antigenic, topologic, and functional properties might have implications
into the physiology of hUT-B1 and other members of the urea
transporter family.
 |
INTRODUCTION |
In the last 10 years, facilitated urea transporters
(UT),1 which play a
major role in urinary concentration mechanism, have been molecularly
characterized in different animal species (1) following the cloning by
functional expression in Xenopus oocytes of the rabbit urea
transporter (2). Currently, two types of mammalian UT can be
distinguished, those that are encoded by the Slc14a2 gene
(type UT-A) and those that are encoded by the Slc14a1 gene
(type UT-B) (3-6). In humans and mouse, these two UT genes occur in tandem on chromosome 18q12 (for humans, see
GenBankTM accession number AC023421) (7-9). The
Slc14a2 gene encodes five alternative spliced isoforms named
UT-A1 to -A5 mainly expressed in the renal tubules, except for UT-A5,
which is expressed only in testis (6, 10). The Slc14a1 gene
only encodes the UT-B1 protein expressed on the red blood cells (RBCs)
(8, 11) and in endothelium of the descending vasa recta irrigating
renal medulla (12, 13). UT-B1 is also expressed in various organs, as
shown in the rat model (14-16).
Recently, it was reported that the urea transport function of human
RBCs and the Kidd (JK) blood group are carried by the same protein,
hUT-B1/Jk (8). The two major codominant alleles of the JK
gene, JK*A and JK*B, have a similar frequency in
Caucasian populations (0.51 and 0.49, respectively) and define the
three common phenotypes Jk(a+b-), Jk(a-b+), and Jk(a+b+) (17, 18). The
genetic basis of the JK*A/JK*B blood group polymorphism is a
single nucleotide transition G838A changing Asp-280 to Asn-280 in the
Jka and Jkb polypeptide, respectively (19).
Because of hUT-B1, RBCs do not undergo excessive cell volume changes
during their transit in the vasa recta irrigating the hypertonic renal
medulla. In addition, they participate in medulla urea sequestration by
taking up urea when flowing in the descending vasa recta and
subsequently releasing urea when flowing in the ascending vasa recta
(20). The presence of hUT-B1 in the endothelium descending vasa recta enables a countercurrent exchange of urea with the ascending vasa recta, a process that also contributes to the urea medulla gradient required for water reabsorption. More recently, renal rUT-B1 has been
shown to be regulated by antidiuretic hormone independently from
medulla hypertonicity (16). Despite these functional properties, hUT-B1
deficiency, which occurs in the rare human phenotype called Jknull (21), is not associated with any obvious clinical
syndrome, except for mild urinary concentration defect, which is,
however, more severe in transgenic UT-B null mice (22, 23). The absence of UT-B1 prevents Jknull RBCs from releasing urea as they
traverse the ascending vasa recta, thus decreasing the
efficiency of the countercurrent exchange and the renal concentration
ability. Although a very rare form of Jknull may be
inherited as a dominant character, most result from homozygous
inheritance of a silent allele at the JK locus
(18) and may arise by at least four distinct molecular mechanisms:
(i) splice site mutations causing the skipping of either exon 6 or exon
7 (5), (ii) missense mutation resulting in a S291P substitution
(24), (iii) nonsense mutation resulting in a Y194Stop substitution
(25), and (iv) partial deletion within the JK locus
encompassing exons 4 and 5 (26).
hUT-B1 is a hydrophobic polypeptide of 389 amino acid residues with a
42.5 kDa apparent molecular mass, which is reduced to 36 kDa following
deglycosylation. Of the 10 cysteine residues present in hUT-B1 and
hUT-A2 proteins, 7 are conserved and aligned at equivalent positions,
but 3 (Cys-25, Cys-30, and Cys-151 on hUT-B1) are present at distinct
positions (Fig. 1) (11). The predicted
membrane topology based on hydropathy plots consists of two repeated
hydrophobic domains spanning the membrane five times each, linked by a
large extracellular loop carrying a single N-glycan chain
attached to Asn-211 (Fig. 1) (11, 24). Each repeat contains a conserved
sequence motif (LPXXTXPF), suggesting an internal
duplication (27). According to the predicted model, both the
N-terminal stretch of 60 amino acids and the C-terminal domain of 35 amino acids are on the cytoplasmic side of the cell membrane, and the
common JK*A/JK*B polymorphism resulting from the D280N
substitution (19) is located in the fourth extracellular loop (Fig. 1).
With this unusual pattern of hydrophobicity, about 70% of hUT-B1 is
embedded in the cell membrane, a feature also observed with the
isoforms of UT-A gene (3). Upon expression in
Xenopus oocytes, hUT-B1 confers a high urea permeability,
which is strongly inhibited by phloretin but poorly inhibited by
para-chloromercuribenzene sulfonate (pCMBS) (28). This
result is surprising in view of the fact that urea permeability of
human RBCs is decreased by both inhibitors (29). This discrepancy
remains to be clarified.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
Hypothetical membrane topology of the urea
transporter protein hUT-B1. A schematic representation is shown
based on hydropathy analysis, which predicted the existence of 10 transmembrane segments organized in two repeat hydrophobic domains
linked by a large glycosylated hydrophobic loop and flanked by
hydrophobic N- and C- terminal domains located within the cells. Of the
10 cysteine residues present in hUT-B1, seven (closed
symbols) are conserved and aligned at equivalent positions in
hUT-A2, and three (Cys-25, Cys-30, and Cys-151) are present in hUT-B1
at distinct positions (open symbols). The
unique functional N-glycosylation site (Asn-211), the tandem
sequence repeat (LPXXTXPF), the
JK*A/JK*B blood group polymorphism ( ), and the
two VG repeat motif ( ) were located. The GenBankTM
accession number of hUT-B1 coding sequence is Y19039.
|
|
The present report has four purposes: (i) to provide direct evidence
that hUT-B1 carries the Jk blood group antigens by flow cytometry
analysis of Jk-K562 transfectants, (ii) to analyze the membrane
topology of hUT-B1 in the RBC membrane, (iii) to characterize the urea
transport mediated by hUT-B1 in an erythroid context by expressing the
protein in the K562 erythroleukemic cell line, and (iv) to examine the
structure-function relationship with respect to plasma membrane
targeting and pCMBS sensitivity of the hUT-B1 protein.
 |
MATERIALS AND METHODS |
Blood Samples and Reagents--
RBC samples from individuals of
common and rare Jk phenotypes were obtained from the Centre National de
Référence sur les Groupes Sanguins (CNRGS, Paris, France).
Restriction endonucleases and modifying enzymes were from New England
Biolabs (Hertfordshire, UK). The [14C]urea (1.96 GBq/mmol) and the [3H]raffinose (188.7 GBq/mmol)
came from Amersham Biosciences and PerkinElmer Life Sciences,
respectively. Pwo DNA polymerase from Roche Molecular Biochemicals was
used for PCR amplification. Nucleotide sequences were determined on
both strands with ThermoSequenase fluorescently labeled primer cycle
sequencing kit from Amersham Biosciences using 5'(Cy5) primers (Genset,
Paris, France) and an automated Alf-Express sequencer (Amersham
Biosciences). The human antiserum containing an alloanti-Jk3
was obtained from an immunized Jk(a-b-) individual also called
Jknull. The human monoclonal antibodies (mAbs)
anti-Jka (IgM, MS15) or anti-Jkb (IgM, MS8) and
the human polyclonal antisera anti-Jka or
anti-Jkb were from Biotest AG (Dreieich, Germany). Rabbit
polyclonal antisera and affinity purified antibodies directed against
the N-terminal region (anti-Nter, residues 8-22) or the C-terminal
region (anti-Cter, residues 377-389) of the hUT-B1/Jk protein were
described previously (8, 12).
Cell Culture, Transfection, and Flow Cytometry
Analysis--
Human erythroleukemic K562 cells were obtained from the
American Type Culture Collection (Manassas, VA) and were grown
in Iscove's modified Dulbecco's medium with Glutamax-1 (Invitrogen) supplemented with penicillin-streptomycin and 10% fetal calf serum. To
establish a stable cell line expressing the Kidd/urea transporter, hUT-B1 cDNAs (nucleotides 9 to 1182) carrying either a G838
(JK*A allele) or an A838 (JK*B allele) were
amplified by PCR from the Jka/Jkb-pT7TS
constructs (19) using SP-1 and AS-1 primers (see Table I), subcloned
into the pCEP4 episomal expression vector (Invitrogen), and transfected
into K562 cells using the Lipofectin reagent according to the
manufacturer's instructions (Invitrogen). Stable transfectants resistant to hygromycin (300 µg/ml) were selected for Jk
antigen expression by immunomagnetic separation using a human anti-Jk3 antiserum and Biomag Goat anti-human-IgG (PerSeptive Biosystems, Connecticut, MA). Stable clones were isolated, and Jka,
Jkb, and Jk3 antigens expression was analyzed by flow
cytometry. Briefly, K562 transfectants (3-5 × 105)
were incubated for 60 min at 22 °C with appropriate antibodies used
at saturating concentration and then washed and stained with 100 µl
of phycoerythrin-conjugated F(ab')2 fragments of goat
anti-human IgG diluted 1:40 (Coulter/Immunotech, Marseille, France).
After another washing step, 20 nM TO-PRO-1,
Molecular Probes (Interchim, Montluçon, France) was added to
the cell suspension 15 min before FACScan analysis (BD PharMingen)
to exclude dead cells (TO-PRO positive-cells).
Kidd/Urea Transporter Proteins Immunoprecipitation and
ABO Immunotyping--
RBC membranes of known ABO phenotypes were
prepared by hypotonic lysis (30) and solubilized in 10 mM
sodium phosphate, pH 7.4, 150 mM NaCl containing 5%
(w/v) Triton X-100 and 1 mM
4-(2-aminoethyl)-benzenesulfonylfluoride (AEBSF, Interchim). The clear
supernatant (22,000 × g for 30 min) was incubated
overnight at 4 °C with affinity-purified antibody anti-Nter of
hUT-B1 (see above), and immunoprecipitates were purified on Protein
A-Sepharose CL-4B (Amersham Biosciences), washed, and eluted by heating
as described (31). The immunoprecipitates were separated by SDS-PAGE
(15% separating gel) and immunoblotted by reaction with the murine
mAbs anti-A (clone 26W2, CNRGS, Paris, France) (1:10 dilution), anti-B
(Ortho Diagnostic System, Raritan, NJ) (1:5 dilution), or the
affinity-purified antibody anti-Cter of hUT-B1 (10 µg/ml). Bound
antibodies were detected with alkaline phosphatase-labeled goat
anti-mouse or anti-rabbit IgG(H+L) (1:800 dilution) and CDP-Star
chemiluminescence reagent (PerkinElmer Life Sciences).
Immunoadsorption Assays--
Right-side-out (ROVs) and
inside-out (IOVs) vesicles were prepared from Jk-positive RBCs and
purified through a barrier of 8% (w/v) dextran T70, as described
previously (32). One volume of each rabbit polyclonal serum anti-Nter
or anti-Cter of hUTB1 was mixed for 2 h at 37 °C with 4 volumes
of sealed vesicles at the protein concentration of 2.5 mg/ml and
subsequently centrifuged at 20,000 × g for 15 min.
Free antibodies in the supernatants and the bound antibodies eluted
from the vesicles by the digitonin method (33) were analyzed by Western
blot on Jk-positive RBC membrane proteins separated by SDS-PAGE and
transferred to nitrocellulose sheets (Schleicher and Schuell, Keene,
NH; 0.1 µm). Bound antibodies were detected with alkaline
phosphatase-labeled goat anti-rabbit IgG (1:800 dilution) and the
alkaline phosphatase substrate kit (Bio-Rad).
Site-directed Mutagenesis and Truncation of the
hUT-B1/Jk cDNA--
All primers used are given in Table
I. Single point mutations C25S, C30S,
C151S, N211I, and C236S were introduced into the Jka
allelic cDNA using a two-step PCR approach with the common SP-1 and
AS-1 primers, in addition to sequence-specific mutagenic primers overlapping each other, AS-2 to 6 and SP-2 to 6, respectively. The
second PCR was performed with 1/100 of each two first PCR reactions.
The double mutation C25S,C30S was generated similarly using the
Jka cDNA carrying the single mutation C25S as initial
PCR matrix. Deletions of nucleotide sequences encoding the first 59 ( N) or the last 30 ( C) amino acids of the Jka
polypeptide were generated by PCR amplification between SP- N and
AS-1 or SP-1 and AS- C primers, respectively. The double N- and
-C-terminal deletion ( N+ C) construct was obtained using SP- N
and AS- C primers. For efficient translation, artificial ATG codon
and Stop codon were inserted at the 5' end of the SP- N and AS- C
primers, respectively. All PCR amplifications were done under stringent
conditions: 94 °C for 45 s (1 cycle); 94 °C for 45 s,
58-72 °C depending of primer pairs used for 30 s, 72 °C for
60 s (30 cycles); 72 °C for 1 min (1 cycle). All mutant
Jka cDNAs were subcloned into the
EcoRV-digested pT7TS plasmid (kindly provided by P. Krieg,
Austin, TX) except for the C151S and C236S mutants, which were
subcloned into KpnI-HindIII-digested pCEP4 vector
and transfected into K562 cells as described above. All constructs were
sequenced on both strands using an automated Alf-Express sequencer
(Amersham Biosciences) or an ABI-Prism 310 Genetic Analyser (Applied
Biosystems, Foster city, CA) to confirm that the correct junctions/mutations were obtained.
View this table:
[in this window]
[in a new window]
|
Table I
Sequence and position of primers used for PCR amplification and
mutagenesis
*, SP and AS for sense and antisense primer, respectively.
**, The nucleotides encoding the amino acid substitutions are
boldface type and double underlined. #, Position +1 refers to
the first nucleotide of the initiation codon (GenBankTM accession
number Y19039). ATG codons and Stop codons are indicated by boldface
type in SP-1, AS-1, SP- N, and AS- C primers. Extraneous sequences
to the Jka cDNA are underlined.
|
|
Oocyte Expression, Flux Measurements, and
Immunocytochemistry--
Capped sense RNAs were transcribed in
vitro from the pT7TS-cDNA constructs linearized with
SmaI restriction enzyme using T7 polymerase and the mCAP
mRNA capping kit from Stratagene (La Jolla, CA). Expression studies
were carried out by microinjection of each cRNA (0.1 ng/oocyte in 50 nl) in collagenase-treated Xenopus laevis
oocytes, and functional tests were performed 3 days after injection as
described previously (24, 28). In urea transport inhibition
experiments, oocytes were incubated in 1 mM pCMBS (Sigma) or 1 mM phloretin (Sigma) for 20 and 10 min, respectively,
before and during the assay at 18 °C. From the same oocyte batches,
groups of three to six oocytes without chorionic membrane were embedded in paraffin as described (34). Sections (7 µm thick) were stained overnight at 4 °C with 10 µg/ml of affinity-purified
antibodies anti-Nter or anti-Cter and visualized with
fluorescein-conjugated goat anti-rabbit IgG (1:100 dilution)
for 1 h at room temperature (35).
Stopped Flow Experiments--
Water and solute transport
analysis were performed at 15 °C by following the 90° light
scattering variations ( exc: 530 nm) using a stopped flow
spectrophotometer (SFM3, Biologic, Claix, France) as described
previously (36). 60 µl of phosphate-buffered saline washed K562 cells
resuspended at the density of 0.5-1.0 × 107 cells/ml
were mixed to an equal volume of hypertonic solution containing solutes
(sorbitol or urea) to create an inwardly directed osmotic gradient of
150 mosM/kg of H2O, and the scattered light intensity variation was followed.
The first part of the curve corresponded to a water efflux to
osmotically equilibrate cells with the external medium and allowed to
calculate the osmotic water permeability coefficient
(Pf). Data averaged from 5 to 10 time courses were
fitted to a double exponential function by using the simplex procedure
of the Biokine software (Biologic), and the apparent
P'f was calculated according to the equation:
P'f = kexp·Vo/S·Vw·((Cin/V(t)) Cout) where Kexp is
the first exponential rate constant;
V(t) is the relative volume
of the K562 cells at time, t;
Vosm/S is the ratio of cell osmolyte
volume to cell surface area (7.94 10 5 cm);
Vw is the molar volume of water (18 cm3/mol), and Cin and
Cout are the initial concentrations of total solute inside and outside the cells, respectively.
The second part of the curve, which was only observed with
Jk transfectants in urea condition, resulted from cell swelling as water accompanied urea influx to maintain the osmotic equilibrium. The analysis of this part of the curve was fitted to a single exponential function using the same software as indicated above, and
the apparent P'urea was calculated using the
following equation: P'urea = kexp·(Impout+Permout)/S·((I'o·V'o/V(t)) Impout) (37), where I'o and
V'o represent the initial concentration of the
impermeant solute and the cell volume, respectively. Impout
and Permout were the external concentrations of impermeant
and permeable solutes, respectively. In some experiments, pCMBS
(0.1-3.0 mM) was added to the cells and hypertonic media 15 min before the shrinkage-swelling measurement. Reversibility was
carried out after addition of 5 mM -mercaptoethanol (Sigma).
 |
RESULTS |
The hUT-B1 Polypeptide Carries Jk and ABO Blood Group
Specificities--
As Northern blot analysis revealed that the K562
erythroleukemic cell line lacked hUT-B1 transcripts (not shown), stable
transfectants expressing the hUT-B1/Jka and
hUT-B1/Jkb allelic cDNAs were established in these
cells. Flow cytometry analysis showed that polyclonal antiserum
anti-Jka strongly reacted with K562-Jka but not
K562-Jkb transfectants, whereas antiserum
anti-Jkb strongly reacted with K562-Jkb but
not K562-Jka transfectants (Fig.
2). Identical results were obtained with human mAbs directed against Jka and Jkb
antigens (not shown). The geometric mean of fluorescence was higher
with Jkb as compared with Jka transfectants
(Fig. 2), presumably because of a better transfection efficiency. As
expected, both transfectants reacted with the human alloanti-Jk3,
indicating that both the JK*A and JK*B alleles
also encode the Jk3 antigenic specificity. In contrast, parental K562 cells did not react with antibodies directed against Jka,
Jkb, or Jk3 antigens (Fig. 2).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 2.
Expression of Kidd blood group antigens on
K562 transfectants. Parental K652 cells (gray line) and
K562 cells transfected with Jka- or Jkb-pCEP4
constructs (dark line) were stained with the human
polyclonal antisera anti-Jka (1:2 dilution),
anti-Jkb (1:2 dilution), or anti-Jk3 (1:50 dilution)
followed by phycoerythrin-goat anti-human IgG (F(ab')2
fragments) and analyzed by flow cytometry as described under
"Materials and Methods." The log of the fluorescence intensity is
shown on the abscissa, and the cell number is shown on the
ordinate. The geometric means were reported for each cell
population analyzed.
|
|
Although hUT-B1 is known to carry a single N-glycan attached
to Asn-211 (Fig. 1) (24), it has not been determined whether this
oligosaccharide chain may carry some blood group determinants. To
address this issue, the hUT-B1 protein was immunopurified from RBCs of
known ABO blood group phenotypes with the affinity-purified anti-Nter
antibody to hUT-B1, and the immunoprecipitate was submitted to SDS-PAGE
and immunoblotted with murine mAbs anti-A or anti-B. hUT-B1 from blood
group A individuals was detected with mAb anti-A only, and hUT-B1 from
B individuals was detected with mAB anti-B only, whereas hUTB1 from AB
individuals was detected with both mAbs anti-A or anti-B (Fig.
3). In contrast, hUT-B1 prepared from group O individuals were unreactive with anti-A or anti-B antibodies (Fig. 3). As a control, all preparations, except that prepared from a
Jknull individual, gave a strong signal with the
affinity-purified anti-Cter antibody to hUT-B1. Altogether, these
results clearly demonstrated that the hUT-B1 polypeptide carries Jk
blood group antigens, and in addition, exhibits ABO antigens attached
to the N-glycan at Asn-211 (Fig. 1).

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 3.
hUT-B1 carries ABO antigens on the
N-linked sugar chain. Immune precipitates
obtained with the affinity-purified antibody directed against the N
terminus of hUT-B1 using Triton X-100 solubilized RBC membranes from
defined ABO phenotypes were separated by SDS-PAGE, transferred to
nitrocellulose sheets, and incubated with the mAbs anti-A or anti-B.
RBC membranes from Jknull donor and the affinity-purified
antibody directed against the C terminus of hUT-B1 were used as
negative and positive controls, respectively. After washings, bound
antibodies were revealed as described under "Materials and
Methods."
|
|
Topology of the N- and C-terminal Ends of hUT-B1--
To provide
experimental evidence that the N and C terminus of hUT-B1 are
intracytoplasmic, immunoadsorption assays of anti-Nter or anti-Cter
antibodies to hUT-B1 onto ROVs and IOVs prepared from human RBCs were
performed. Antibodies remaining unabsorbed and those acid-eluted from
each type of vesicles were immunoblotted on RBC membrane proteins from
Jk-positive individuals as compared with the starting serum (anti-Nter
or anti-Cter). These studies revealed that the anti-Nter or anti-Cter
antibodies could not be recovered from acid eluate from ROVs (Fig.
4) and remained in the supernatant. In
contrast, the antibodies were recovered in the acid eluate but not in
the supernatant from IOVs. As a control, both starting sera reacted
with hUT-B1 as a diffuse band of 46-69 kDa, as expected. These data
are in agreement with the hydrophobicity profile of hUT-B1 predicting
an intracellular orientation of the N and C terminus of the polypeptide
(Fig. 1).

View larger version (88K):
[in this window]
[in a new window]
|
Fig. 4.
Western blot analysis of antibodies in
supernatants and eluates from ROVs and IOVs. Membrane proteins
from Jk-positive RBCs (100 µg/lane) were separated on SDS-PAGE,
transferred onto nitrocellulose, and immunologically stained with
supernatants (1:250 dilution) and acid eluates (1:250 dilution) from
IOVs and ROVs preincubated with antibodies against the N or C terminus
of hUT-B1. Staining with serum before immunoadsorption assay (1:500
dilution) was performed as a positive control. After extensive
washings, antibodies bound to hUT-B1 (46-69 kDa) were visualized as
described under "Materials and Methods."
|
|
Membrane Expression and Urea Transport of hUT-B1 in
Oocytes--
Membrane expression and urea transport activity of wild
type and selected mutants of hUT-B1 were investigated in the
Xenopus expression system. Urea uptake at 90 s was
performed from oocytes injected with the corresponding cRNAs, and
membrane expression was analyzed by immunohistochemistry of oocyte
sections stained with affinity-purified anti-Nter or anti-Cter
antibodies to hUT-B1.
First, immunocytochemical analysis revealed that the
Jka and Jkb allelic forms of hUT-B1 were
expressed at the plasma membrane of cRNA-injected oocytes (Fig.
5, B and C),
whereas water-injected oocytes remain unstained with both the anti-Nter
or anti-Cter antibodies (Fig. 5A). Transport studies showed
that both proteins mediated a urea flux of the same rate inhibited
strongly by phloretin as reported previously (Fig.
6) (28), but not (or very mildly in other
experiments) by pCMBS.

View larger version (143K):
[in this window]
[in a new window]
|
Fig. 5.
Immunocytochemical analysis. Sections of
oocytes injected with water (A) as negative control or cRNAs
encoding the JK*A (B and D) or
JK*B (C) alleles and the mutant JK*A
alleles N (E), C (F), N211I (G),
C30S (H) or C25S,C30S (I). The sections
A-C, F-I, and D and E
were stained with affinity-purified antibodies against the N or C
terminus of hUT-B1, respectively, as described under "Materials and
Methods." Negative control for antibodies against the C terminus
tested with water injected oocytes was identical to section
A (not shown). Images were generated using a Nikon Eclipse TE300
microscope (Nikon, Paris, France) (×40 objective) with epifluorescence
illumination and treated with a Biocom informatic system of image
integration (Biocom, les Ulis, France).
|
|

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 6.
Functional analysis of wild type and hUT-B1
mutant proteins in Xenopus oocytes. Urea uptake
and effect of pCMBS and phloretin on urea transport of oocytes injected
with cRNAs encoding the JK*A or JK*B alleles and
the following mutant JK*A alleles: N, C, N+ C,
N211I, C25S, C30S, and C25S,C30S. For each oocyte, 0.1 ng of cRNA were
injected, and at least six oocytes/point were preincubated or not with
pCMBS (1 mM) or phloretin (1 mM) containing
medium for 20 and 10 min, respectively. Inhibitors were maintained
during the whole experiment. The urea transport assay was initiated by
suspending individual oocytes in 0.2 ml of Barth's solution containing
8 µCi/ml [14C]urea (145 µM) and 5 µCi/ml [3H]raffinose as a control of oocyte plasma
membrane integrity. The urea uptake was stopped after 90 s of
incubation by addition of 3 ml of ice-cold Barth's solution and
followed by two fast washes with 5 ml of the same solution. After
solubilization, the samples were subjected to liquid scintillation in a
counter, and the urea permeability (P urea) was calculated
from the oocyte-associated amount of [14C]urea at 90 s, corrected for the optically determined oocyte surface area.
Water-injected oocytes served as negative controls. Data (mean ± S.E.) correspond to one representative experiment of at least
three.
|
|
Next, we examined the effect of mutations of the functional
N-glycosylation consensus site and of cysteine residues
Cys-25 and Cys-30 specific to hUT-B1 (Fig. 1). Oocytes injected with cRNAs encoding mutant forms of the JK*A allele carrying the
substitutions N211I, C30S (Fig. 5, G and H), and
C25S (not shown) normally expressed the mutant proteins at the plasma
membrane and transported urea similarly to the wild type
Jka protein (Fig. 6). When a cRNA preparation encoding the
Jka polypeptide truncated of the last 30 C-terminal
residues was injected into oocytes, a weak decrease of the plasma
membrane expression was noted without significant change in urea
transport activity (Figs. 5F and 6). Conversely, the
deletion of the first 59 N-terminal residues completely abolished
expression at the oocyte membrane, therefore precluding any transport
function study (Figs. 5E and 6). As this N-terminal domain
contains two cysteines Cys-25 and Cys-30, which could play some role in
the UT function, the protein-protein interactions, and the
addressing to the plasma membrane, these residues were mutated to
serine. Interestingly, neither the C25S nor the C30S mutations
alone affected membrane expression and transport activity
(Figs. 5H and 6), but double mutation of the two
cysteines (C25S,C30S) completely abolished membrane
expression in oocytes (Fig. 5I). In agreement with
these observations, no urea transport activity was detected when oocyte membrane expression was absent (Figs. 5 and 6). In all instances, when
a urea transport occurs, phloretin behaved as a potent inhibitor, whereas pCMBS did not or behaved very poorly (Fig. 6).
Water and Urea Permeabilities of K562 Transfectants--
To
understand why urea transport mediated by the cloned hUT-B1 expressed
in Xenopus oocytes and the physiological UT of human RBCs
differ in their sensitivity to pCMBS, the urea transport function of
hUT-B1 was analyzed in an erythroid context following expression in the
erythroleukemic cell line K562. Accordingly, cell suspensions of
K562-Jka or K562-Jkb transfectants were rapidly
mixed with a hyperosmolar solution to drive osmotic water efflux and
cell shrinking. The rate of increase in scattered light intensity
corresponding to the cell shrinking was measured in K562 cells with
(0.15 M) sorbitol as osmolyte (Fig.
7A). The apparent
P'f values in cm s 1 ± S.D. calculated
were 1.50 ± 0.47 × 10 2, 1.20 ± 0.65 × 10 2, and 1.48 ± 0.28 × 10 2 for wild type K562 cells, K562-Jka, and
K562-Jkb transfectants, respectively (Table
II). When the hyperosmolarity was
performed with (0.15 M) urea, the light scattering increase in wild type K562 cells (P'f = 1.71 ± 0.53 × 10 2 cm s 1, n = 5) was identical to the rate increase observed with sorbitol excluding
an endogenous urea transport activity (Fig. 7A). However, only the K562-Jka and -Jkb transfectants
presented, after a brief scattered light intensity increase due to the
efflux of water, a significant decrease of light scattering due to the
cell swelling directly related to the osmotic influx of water
accompanying urea uptake to ensure osmotic equilibrium (Fig.
7B). The P'urea values calculated
were 1.78 ± 0.34 × 10 5 and 3.35 ± 0.9 × 10 5 cm s 1 for
K562-Jka and Jkb, respectively (Table II).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Urea transport analysis in K562 transfectants
by stopped flow light scattering. A, stopped flow
curves obtained with wild type K562 cells submitted to 150 mosM/kg H2O urea or sorbitol gradients. The
light scattering increase was similar with both gradients.
B, typical stopped flow curves obtained with
K562-Jka transfectant submitted to a 150 mosM/kg H2O urea gradient. The increase light
intensity corresponding to initial water efflux and the decrease light
intensity resulting from water associated with the solute influx were
recorded during 18 s. The curve was fitted to single exponential,
and P'urea values were calculated as described
under "Materials and Methods" (as well as in Table II). For
inhibition experiments, 0.3 mM pCMBS was added 15 min
before and during the assays. To test the reversibility of pCMBS
inhibition, subsequent incubation for 5 min in 5 mM
-mercaptoethanol ( -me) was performed before the
assays. C, pCMBS sensitivity of urea transport of wild type
(Jka) and mutant Jka(C151S) and
Jka(C236S) polypeptides expressed in K562 cells. The
transfectants were incubated with increasing concentration of pCMBS
(0-3 mM) 15 min before the assay as described under
"Materials and Methods." The mean data from three experiments are
shown.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Water and urea permeabilities of K562-Jka and -Jkb
transfectants
The P'f and P'urea corresponding
to the apparent water and urea permeabilities were calculated from
stopped flow analysis of K562-Jka or -Jkb transfectants
and parental K562 cells as described under "Materials and Methods"
(see also Fig. 6). Data are presented as mean ± S.E.
(n), where n indicates the number of experiments.
Statistical significances are indicated. ND, undetermined. *,
p < 0.02 by Student's t test.
|
|
The urea permeability of K562-Jka was measured in the
presence of 0.3 mM pCMBS. We found that the urea flux was
strongly reduced to 20%, a value close to that reported for RBCs (29).
Moreover, pCMBS inhibition was reversed by 5 mM
-mercaptoethanol (Fig. 7B). Identical results were
obtained with K562-Jkb (not shown). Next, to identify the
cysteine residues involved in the pCMBS sensitivity, the unique
extracellular cysteine Cys-236 and the intramembranous cysteine Cys-151
specific of hUT-B1, near the cell surface, were mutated to serine (Fig.
1). Thus the pCMBS sensibility of K562-Jka and of two K562
transfectants expressing Jka mutant proteins carrying the
C151S and C236S substitutions at the same level were compared. All
exhibited comparable P'urea values found for
K562-Jka and Jkb (Table II). Fig. 7C
shows that K562-Jka and K562-C151S had identical
dose-response inhibition by pCMBS, whereas the K562-C236S exhibited a
higher sensitivity. At 0.3 mM pCMBS, the remaining
transport activities were 55% for the former transfectants and
only 20% for the latter. At 3 mM pCMBS, the urea transport
activity of all samples was completely inhibited (Fig. 7C).
Thus, the urea transport mediated by hUT-B1 is pCMBS-sensitive in an
erythroid context, but Cys-151 and Cys-236, at least alone, are not
involved in pCMBS inhibition.
 |
DISCUSSION |
The hUT-B1 Protein carries Kidd (Jk) as Well as ABO Blood Group
Antigens--
The formal proof that the hUT-B1 gene encodes
the Jka and Jkb blood group antigens was
provided by showing that human mAbs and polyclonal antisera
anti-Jka or anti-Jkb only react with K562 cells
transfected with Jka or Jkb allelic forms of
the cloned hUT-B1 urea transporter, respectively. In addition, these
studies showed that the N-glycan chain attached to Asn-211
of hUT-B1 carries ABO blood group determinants as found for the
N-glycan chains of Band-3, Band-4.5 (glucose
transporter), and AQP-1 (38-40). Knowing that all hUT-B1 molecules
appear glycosylated in RBCs (8), less than 1% of RBC ABO determinants
is carried by the hUT-B1 protein, which is present at a low copy number
(1.4 × 104 molecules/cell), as compared with Band-3
and AQP-1 proteins, which are present at high copy numbers
(106 and 2 × 105 molecules/cell,
respectively). Thus, the antigenic properties of hUT-B1 and its
expression in renal tissues might have biological implications in
kidney transplantation
Topological and Functional Properties of hUT-B1--
In accordance
with the predicted membrane topology of hUT-B1 (11), expression studies
reported here indirectly confirmed the extracellular exposure of the
third and fourth loops carrying the N-glycosylation site (at
Asn-211) and of the JK*A/JK*B allelic polymorphism, respectively (Fig. 1). Moreover, immunoadsorption studies
provide evidence for the intracellular orientation of the C and N
terminus of the protein in RBCs (Fig. 1). Similar membrane topology has
been found for other membrane proteins such as the anion exchanger
Band-3 (AE1) (41) and the water channel AQP-1 (42). Whether the N-
and/or C-terminal domains play some role in the UT function and/or
protein-protein interaction with other membrane components is presently
not known. However, our preliminary results in Xenopus
oocytes suggested that cysteines Cys-25 and Cys-30 together (not alone)
within the 59 N-terminal amino acids domain are critical for correct
addressing and insertion of hUT-B1 in the plasma membrane. Conversely,
neither the deletion of the last 30 C-terminal nor the
JK*A/JK*B polymorphism had any affect on the
expression level and urea transport activity of hUT-B1. Although
N-glycosylation often determines membrane expression level
and addressing polypeptides to the membrane, (43-45), we found that
unglycosylated hUT-B1 polypeptide is normally addressed and inserted in
the oocyte plasma membrane and exhibited a normal urea transport
activity as reported for AQP2 (46, 47).
Another goal of this study was to analyze protein expression and urea
transport activity of hUT-B1 into the erythroleukemic K562 cells to
investigate the sensitivity to mercurial agents in an erythroid
context. Indeed, recombinant hUT-B1 in oocytes confers a urea
permeability, which is poorly inhibited by pCMBS, whereas the native UT
of human RBCs is strongly inhibited by mercurial agents (28, 29).
Accordingly, the rates of volume change of wild type K562 cells and
K562-Jka and -Jkb transfectants submitted to an
osmotic sorbitol gradient were measured by light scattering stopped
flow experiments. Under these conditions, parental and K562
transfectants exhibited relatively high apparent water permeabilities
close to published values (48). The absence of a further increase in
K562-Jka and -Jkb transfectants confirmed that
the hUT-B1 is not a water channel as reported previously (28). When an
osmotic urea gradient was imposed, the urea transport
capacity of hUT-B1 was preserved in K562-Jka and
-Jkb transfectants, the calculated
P'urea values being of 1.78 ± 0.34 × 10 5 and 3.35 ± 0.9 × 10 5 cm
s 1, respectively. The difference of
P'urea values observed might be related to the
difference in the transporter density in K562 transfectants, as
suggested by the shift in fluorescence intensity detected by the
alloanti-Jk3 antibody (Fig. 2).
We further demonstrated that the urea flux mediated by
K562-Jka and -Jkb transfectants was strongly
inhibited by a low concentration of pCMBS and was reversed by
-mercaptoethanol, as reported for the UT of human RBCs (49). These
findings suggest that the low pCMBS sensitivity in Xenopus
oocytes reported previously was probably related to membrane
environmental factors (lipid and protein) specific to this heterologous
expression system (50). Thus, it is possible that hUT-B1 adopts a
different conformation in oocyte and red cell membranes, which could
modify the accessibility of the pCMBS to the different cysteines.
However, a strong pCMBS inhibition was observed when oocytes were
injected with HUT11 cRNAs, a rare variant of the RBC urea transporter
exhibiting three Val-Gly repeat motifs after proline 227 (third
extracellular loop) versus 2 Val-Gly in the physiological
hUT-B1 transporter (Fig. 1) (11, 28). As pCMBS inhibits urea/water
transports by reacting with sulfhydryl groups of proteins, the unique
cysteine Cys-236 in the third extracellular loop close to the site of
the dipeptide insertion was mutated to serine (Fig. 1). In parallel,
the intramembranous cysteine Cys-151 specific of hUT-B1, near the cell
surface, was also mutated. Our results indicated that the urea flux
measured in K562-Jka(C151S) and K562-Jka(C236S)
transfectants was not affected by pCMBS but was even increased in the
latter variant. As a single cysteine mutation cannot abolish pCMBS
inhibition, as reported for AQP1 (51), we cannot exclude that the pCMBS
sensibility results from a combination of several cysteines. Moreover,
it can be stressed that the absence of the Val-Gly dipeptide is
sufficient to strongly reduce pCMBS inhibition in the oocyte expression
system, whereas the C236S substitution increases pCMBS sensitivity in
K562 cells. Presumably, such opposite effects might be due to
conformation changes of the third extracellular loop of hUT-B1 via
amino acid sequence changes, which in turn modify pCMBS accessibility
to cysteine residues. These observations suggest a key role of the
third extracellular loop connecting the two hydrophobic half-parts of
hUT-B1 in the urea transport function.
Our results therefore, indicate that functional assays of UT and
their modulation by pharmacological agents should be considered with
great caution when analyzed in heterologous expression systems that may
not reflect the true physiological properties exhibited in
physiological tissues. Altogether, these investigations provide new
molecular insights in the membrane topology of hUT-B1 as well as
structure-function relationships regarding hUT-B1 and presumably other
members of the UT-family, which might lead to the design of novel
diuretic molecules.
 |
ACKNOWLEDGEMENT |
We thank Pierre Gane (Institut National
de Transfusion Sanguine, Paris, France) for flow cytometry analysis.
 |
FOOTNOTES |
*
This investigation was supported in part by the Institut
National de la Santé et de la Recherche Médicale (INSERM).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Göteborg University, Box 462, SE405 30 Göteborg, Sweden.
§
To whom correspondence should be addressed. Tel.:
33-1-44-49-30-00; Fax: 33-1-43-06-50-19; E-mail
cartron@idf.inserm.fr.
Published, JBC Papers in Press, July 1, 2002, DOI 10.1074/jbc.M205073200
 |
ABBREVIATIONS |
The abbreviations used are:
UT, urea
transporter;
RBC, red blood cell;
Kidd, Jk;
ROV, right-side out
vesicule;
IOV, inside-out vesicule;
mAb, monoclonal antibody;
pCMBS, para-chloromercuribenzene sulfonate;
Cter, C terminus;
Nter, N terminus;
TO-PRO-1, Quinolinium,4[(3-methyl-2(3H)-benzothiazoPylidene)methyl]-1-[3-trimethyPammonio)propyl]diodide.
 |
REFERENCES |
| 1.
|
Bagnasco, S. M.
(2000)
Cell Physiol Biochem.
10,
379-384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
You, G.,
Smith, C. P.,
Kanai, Y.,
Lee, W. S.,
Stelzner, M.,
and Hediger, M. A.
(1993)
Nature
365,
844-847[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Sands, J. M.,
Timmer, R. T.,
and Gunn, R. B.
(1997)
Am. J. Physiol.
273,
F321-F339[Medline]
[Order article via Infotrieve]
|
| 4.
|
Bagnasco, S. M.,
Peng, T.,
Janech, M. G.,
Karakashian, A.,
and Sands, J. M.
(2001)
Am. J. Physiol.
281,
F400-F406
|
| 5.
|
Lucien, N.,
Sidoux-Walter, F.,
Olives, B.,
Moulds, J., Le,
Pennec, P. Y.,
Cartron, J. P.,
and Bailly, P.
(1998)
J. Biol. Chem.
273,
12973-12980[Abstract/Free Full Text]
|
| 6.
|
Smith, C. P.,
and Rousselet, G.
(2001)
J. Membr. Biol.
183,
1-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Fenton, R. A.,
Hewitt, J. E.,
Howorth, A.,
Cottingham, C. A.,
and Smith, C. P.
(1999)
Cytogenet. Cell Genet.
87,
95-96[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Olives, B.,
Mattei, M. G.,
Huet, M.,
Neau, P.,
Martial, S.,
Cartron, J. P.,
and Bailly, P.
(1995)
J. Biol. Chem.
270,
15607-15610[Abstract/Free Full Text]
|
| 9.
|
Olives, B.,
Martial, S.,
Mattei, M. G.,
Matassi, G.,
Rousselet, G.,
Ripoche, P.,
Cartron, J. P.,
and Bailly, P.
(1996)
FEBS Lett.
386,
156-160[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Fenton, R. A.,
Howorth, A.,
Cooper, G. J.,
Meccariello, R.,
Morris, I. D.,
and Smith, C. P.
(2000)
Am. J. Physiol.
279,
C1425-C1431
|
| 11.
|
Olives, B.,
Neau, P.,
Bailly, P.,
Hediger, M. A.,
Rousselet, G.,
Cartron, J. P.,
and Ripoche, P.
(1994)
J. Biol. Chem.
269,
31649-31652[Abstract/Free Full Text]
|
| 12.
|
Xu, Y.,
Olives, B.,
Bailly, P.,
Fischer, E.,
Ripoche, P.,
Ronco, P.,
Cartron, J. P.,
and Rondeau, E.
(1997)
Kidney Int.
51,
138-146[Medline]
[Order article via Infotrieve]
|
| 13.
|
Promeneur, D.,
Rousselet, G.,
Bankir, L.,
Bailly, P.,
Cartron, J. P.,
Ripoche, P.,
and Trinh-Trang-Tan, M. M.
(1996)
J. Am. Soc. Nephrol.
7,
852-860[Abstract]
|
| 14.
|
Tsukaguchi, H.,
Shayakul, C.,
Berger, U. V.,
and Hediger, M. A.
(1998)
Am. J. Physiol.
275,
F319-F324[Medline]
[Order article via Infotrieve]
|
| 15.
|
Timmer, R. T.,
Klein, J. D.,
Bagnasco, S. M.,
Doran, J. J.,
Verlander, J. W.,
Gunn, R. B.,
and Sands, J. M.
(2001)
Am. J. Physiol.
281,
C1318-C1325
|
| 16.
| Trinh-Trang-Tan, M.-M., Lasbennes, F., Gane, P., Roudier, N., Ripoche,
P., Cartron, J. P., and Bailly, P. (2002) Am. J. Physiol. 280, in press
|
| 17.
|
Race, R. R.,
and Sange, R.
(1975)
Blood Groups in Man
, pp. 178-260, Blackwell, Oxford
|
| 18.
|
Daniels, G.
(1995)
Human Blood Groups
, pp. 440-451, Blackwell, Oxford
|
| 19.
|
Olives, B.,
Merriman, M.,
Bailly, P.,
Bain, S.,
Barnett, A.,
Todd, J.,
Cartron, J. P.,
and Merriman, T.
(1997)
Hum. Mol. Genet.
6,
1017-1020[Abstract/Free Full Text]
|
| 20.
|
Macey, R. I.,
and Yousef, L. W.
(1988)
Am. J. Physiol.
254,
C669-C674[Medline]
[Order article via Infotrieve]
|
| 21.
|
Pinkerton, F. J.,
Mermod, L. E.,
Liles, B. A.,
Jack, J. A., Jr.,
and Noades, J.
(1959)
Vox Sang.
4,
155-160[Medline]
[Order article via Infotrieve]
|
| 22.
|
Sands, J. M.,
Gargus, J. J.,
Frohlich, O.,
Gunn, R. B.,
and Kokko, J. P.
(1992)
J. Am. Soc. Nephrol.
2,
1689-1696[Abstract]
|
| 23.
|
Yang, B.,
Bankir, L.,
Gillespie, A.,
Epstein, C. J.,
and Verkman, A. S.
(2002)
J. Biol. Chem.
277,
10633-10637[Abstract/Free Full Text]
|
| 24.
|
Sidoux-Walter, F.,
Lucien, N.,
Nissinen, R.,
Sistonen, P.,
Henry, S.,
Moulds, J.,
Cartron, J. P.,
and Bailly, P.
(2000)
Blood
96,
1566-1573[Abstract/Free Full Text]
|
| 25.
|
Irshaid, N. M.,
Eicher, N. I.,
Hustinx, H.,
Poole, J.,
and Olsson, M. L.
(2002)
Br. J. Haematol.
116,
445-453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Lucien, N.,
Chiaroni, J.,
Cartron, J. P.,
and Bailly, P.
(2002)
Blood
99,
1079-1081[Abstract/Free Full Text]
|
| 27.
|
Rousselet, G.,
Ripoche, P.,
and Bailly, P.
(1996)
Am. J. Physiol.
270,
F554-F555[Medline]
[Order article via Infotrieve]
|
| 28.
|
Sidoux-Walter, F.,
Lucien, N.,
Olives, B.,
Gobin, R.,
Rousselet, G.,
Kamsteeg, E. J.,
Ripoche, P.,
Deen, P. M.,
Cartron, J. P.,
and Bailly, P.
(1999)
J. Biol. Chem.
274,
30228-30235[Abstract/Free Full Text]
|
| 29.
|
Macey, R. I.,
and Farmer, R. E.
(1970)
Biochim. Biophys. Acta
211,
104-106[Medline]
[Order article via Infotrieve]
|
| 30.
|
Steck, T. L.,
and Kant, J. A.
(1974)
Methods Enzymol.
31,
172-180[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Bloy, C.,
Blanchard, D.,
Lambin, P.,
Goossens, D.,
Rouger, P.,
Salmon, C.,
and Cartron, J. P.
(1987)
Blood
69,
1491-1497[Abstract/Free Full Text]
|
| 32.
|
Boyle, J. M.,
Whetton, A. D.,
Dexter, T. M.,
Meeran, K.,
and Baldwin, S. A.
(1985)
EMBO J.
4,
3093-3098[Medline]
[Order article via Infotrieve]
|
| 33.
|
Jenkins, D. E., Jr.,
and Moore, W. H.
(1977)
Transfusion
17,
110-114[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
McLean, I. W.,
and Nakane, P. K.
(1974)
J. Histochem. Cytochem.
22,
1077-1083[Abstract]
|
| 35.
|
Mulders, S. M.,
Knoers, N. V.,
Van Lieburg, A. F.,
Monnens, L. A.,
Leumann, E.,
Wuhl, E.,
Schober, E.,
Rijss, J. P.,
Van Os, C. H.,
and Deen, P. M.
(1997)
J. Am. Soc. Nephrol.
8,
242-248[Abstract]
|
| 36.
|
Laize, V.,
Rousselet, G.,
Verbavatz, J. M.,
Berthonaud, V.,
Gobin, R.,
Roudier, N.,
Abrami, L.,
Ripoche, P.,
and Tacnet, F.
(1995)
FEBS Lett.
373,
269-274[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Gerbeau, P.,
Guclu, J.,
Ripoche, P.,
and Maurel, C.
(1999)
Plant J.
18,
577-587[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Fukuda, M.,
and Fukuda, M. N.
(1981)
J. Supramol. Struct. Cell Biochem.
17,
313-324[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Anstee, D. J.
(1990)
Vox Sang.
58,
1-20[Medline]
[Order article via Infotrieve]
|
| 40.
|
Smith, B. L.,
Preston, G. M.,
Spring, F. A.,
Anstee, D. J.,
and Agre, P.
(1994)
J. Clin. Invest.
94,
1043-1049[Medline]
[Order article via Infotrieve]
|
| 41.
|
Lux, S. E.,
John, K. M.,
Kopito, R. R.,
and Lodish, H. F.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
9089-9093[Abstract/Free Full Text]
|
| 42.
|
Preston, G. M.,
and Agre, P.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
11110-11114[Abstract/Free Full Text]
|
| 43.
|
Iolascon, A.,
D'Agostaro, G.,
Perrotta, S.,
Izzo, P.,
Tavano, R.,
and Miraglia del Giudice, B.
(1996)
Haematologica
81,
543-559[Abstract/Free Full Text]
|
| 44.
|
Varki, A.
(1997)
FASEB J.
11,
248-255[Abstract]
|
| 45.
|
Lee, S., Wu, X.,
Reid, M.,
Zelinski, T.,
and Redman, C.
(1995)
Blood
85,
912-916[Abstract/Free Full Text]
|
| 46.
|
Baumgarten, R.,
Van De Pol, M. H.,
Wetzels, J. F.,
Van Os, C. H.,
and Deen, P. M.
(1998)
J. Am. Soc. Nephrol.
9,
1553-1559[Abstract]
|
| 47.
|
Bai, L.,
Fushimi, K.,
Sasaki, S.,
and Marumo, F.
(1996)
J. Biol. Chem.
271,
5171-5176[Abstract/Free Full Text]
|
| 48.
|
Umenishi, F.,
and Verkman, A. S.
(1998)
Genomics
47,
341-349[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Mannuzzu, L. M.,
Moronne, M. M.,
and Macey, R. I.
(1993)
J. Membr. Biol.
133,
85-97[Medline]
[Order article via Infotrieve]
|
| 50.
|
Fievet, B.,
Perset, F.,
Gabillat, N.,
Guizouarn, H.,
Borgese, F.,
Ripoche, P.,
and Motais, R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
10996-11001[Abstract/Free Full Text]
|
| 51.
|
Preston, G. M.,
Jung, J. S.,
Guggino, W. B.,
and Agre, P.
(1993)
J. Biol. Chem.
268,
17-20[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. A. Ludden, R. M. Stohrer, K. J. Austin, R. L. Atkinson, E. L. Belden, and H. J. Harlow
Effect of protein supplementation on expression and distribution of urea transporter-B in lambs fed low-quality forage
J Anim Sci,
April 1, 2009;
87(4):
1354 - 1365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Godara, C. Smith, J. Bosse, M. Zeidel, and J. Mathai
Functional characterization of Actinobacillus pleuropneumoniae urea transport protein, ApUT
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 2009;
296(4):
R1268 - R1273.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. MacIver, C. P. Smith, W. G. Hill, and M. L. Zeidel
Functional characterization of mouse urea transporters UT-A2 and UT-A3 expressed in purified Xenopus laevis oocyte plasma membranes
Am J Physiol Renal Physiol,
April 1, 2008;
294(4):
F956 - F964.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Chen, O. Frohlich, Y. Yang, J. D. Klein, and J. M. Sands
Loss of N-Linked Glycosylation Reduces Urea Transporter UT-A1 Response to Vasopressin
J. Biol. Chem.,
September 15, 2006;
281(37):
27436 - 27442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Stewart, C. P. Smith, and G. J. Cooper
Molecular characterization of the mercurial sensitivity of a frog urea transporter (fUT)
Am J Physiol Renal Physiol,
June 1, 2006;
290(6):
F1437 - F1442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Sands and D. G. Bichet
Nephrogenic Diabetes Insipidus
Ann Intern Med,
February 7, 2006;
144(3):
186 - 194.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-M. Trinh-Trang-Tan, J.-P. Cartron, and L. Bankir
Molecular basis for the dialysis disequilibrium syndrome: altered aquaporin and urea transporter expression in the brain
Nephrol. Dial. Transplant.,
September 1, 2005;
20(9):
1984 - 1988.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Yang and L. Bankir
Urea and urine concentrating ability: new insights from studies in mice
Am J Physiol Renal Physiol,
May 1, 2005;
288(5):
F881 - F896.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zhang and A. Edwards
Theoretical effects of UTB urea transporters in the renal medullary microcirculation
Am J Physiol Renal Physiol,
October 1, 2003;
285(4):
F731 - F747.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Yang and A. S. Verkman
Analysis of Double Knockout Mice Lacking Aquaporin-1 and Urea Transporter UT-B. EVIDENCE FOR UT-B-FACILITATED WATER TRANSPORT IN ERYTHROCYTES
J. Biol. Chem.,
September 20, 2002;
277(39):
36782 - 36786.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|